SEC 8-K
SEC 8-K: Item 5.02, 5.03, 5.07, 9.01
Official SEC filing update. Items: 5.02, 5.03, 5.07, 9.01.
Item 5.02, 5.03, 5.07, 9.01Accession 0001193125-26-257593
CRISPR Therapeutics AG (CRSP) Financials, Dividends & Stock Info
Explore comprehensive financial data for CRISPR Therapeutics AG, provided completely free. Analyze revenue, net income, profit margins, dividend history, and key financial ratios to make informed investment decisions.
Data as of (602 days ago)|Source: SEC EDGAR
The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results.
Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing. About · Methodology
CRSPHealth Care
CRISPR Therapeutics AG (CRSP) is a biotechnology company. The company reports annual revenue of $37M and net loss of $366M.
CRISPR Therapeutics AG Key Financials
Revenue (TTM)↓ 90.6%
$37.3M
Net Income (TTM)↓ 58.8%
$-366.3M
Data from SEC EDGAR filings. TTM = Trailing Twelve Months.
CRISPR Therapeutics AG Financial Health ScoreFY2025
0/100
Weak financial health; requires careful evaluation
-3 pts YoYProfitability15Liquidity70Growth10Cash Flow15Efficiency18
This Financial Health Score is a proprietary metric calculated from SEC EDGAR filings for educational and informational purposes only. It does not constitute investment advice or a recommendation to buy or sell any security. Results vary significantly by industry. Conduct your own research before making investment decisions.
Data Highlights
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
CRISPR Therapeutics AG Official SEC Updates
Official filing updates from SEC EDGAR. Billiver stores internal evidence snapshots for verification, but this page links to the SEC source instead of republishing full filing text.
Open SEC filing
SEC 10-Q
SEC 10-Q
Official SEC filing update.
10-QAccession 0001193125-26-204188
SEC 8-K
SEC 8-K: Item 2.02, 9.01
Official SEC filing update. Items: 2.02, 9.01.
Item 2.02, 9.01Accession 0001193125-26-204147
SEC DEF 14A
SEC DEF 14A
Official SEC filing update.
DEF 14AAccession 0001193125-26-165158
SEC 8-K
SEC 8-K: Item 1.01, 2.03, 3.02, 9.01
Official SEC filing update. Items: 1.01, 2.03, 3.02, 9.01.
Item 1.01, 2.03, 3.02, 9.01Accession 0001193125-26-108333
Source: SEC EDGAR · 5 filings
Informational only. Not investment advice.
CRISPR Therapeutics AG Recent Events
Leadership Change
Shareholder Vote
Governance Amendment
Earnings Results
Material Agreement
Source: SEC EDGAR 8-K Filings
5-Year Revenue & Net Income Trend
Chart shows fiscal year data from SEC EDGAR filings. Hover over data points for details.
As of FY2025 · SEC 10-K · Updated Jul 2, 2026
About CRISPR Therapeutics AG
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
- Industry
- Biotechnology
Valuation
Valuation Data UnavailablePrice-based valuation metrics (P/E, P/B) require real-time stock price data which is not included in SEC filings.
Benjamin Graham: Graham recommended P/E ratio not exceed 15 for reasonable valuation. Understanding valuation metrics
Profitability
Profitability Data Under ReviewRevenue (TTM)$37M
Net Income (TTM)-$366M (Loss)
Profitability metrics are being verified. Some SEC filing data may require additional validation.
Warren Buffett: Buffett looks for consistent ROE above 20% as a sign of competitive advantage. How to evaluate profitability
Financial Health
Balance Sheet Data LimitedInsufficient data to assess financial health.
Peter Lynch: Lynch: normal balance sheet has 75% equity, 25% debt. Understanding financial health
Dividend
Dividend Data UnavailableDividend yield data is not available from SEC filings. Check the company's investor relations page for dividend information.
As of FY2025 · SEC 10-K · Updated Jul 2, 2026
CRISPR Therapeutics AG 10-Year Revenue, Profit & Cash Flow History
Annual Financials
FY2025 - FY2016| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.5M(-90.6%) | $37.3M(-89.9%) | $371.2M(+30885.5%) | $1.2M(-99.9%) | $915.0M(+127154.9%) | $719,000(+119.2%) | $328,000(-93.6%) | $5.2M(+1990.7%) | $247,000(0.0%) | $247,000(0.0%) |
| Net Income | $-581,599,000(-58.8%) | $-366,252,000(-138.4%) | $-153,610,000(+76.4%) | $-650,175,000(-272.2%) | $377.7M(+208.3%) | $-348,865,000(-621.8%) | $66.9M(+388.5%) | $-23,177,000(+9.1%) | $-25,503,000(-263.9%) | $-7,009,000(+72.5%) |
| Total Assets | $2.3B | $2.2B | $2.2B | $2.2B | $2.8B | $1.8B | $1.1B | $489.0M | $271.3M | $345.0M |
| Total Debt | - | - | - | - | - | - | - | - | - | - |
| Total Equity | $1.9B | $1.9B | $1.9B | $1.9B | $2.4B | $1.7B | $939.4M | $187.8M | $232.8M | $232.8M |
| Profit Margin | -16569.8% | -981.5% | -41.4% | -54271.7% | 41.3% | -48520.9% | 20383.5% | -448.8% | -10325.1% | -2837.7% |
| ROE | -30.3% | -19.0% | -8.2% | -34.7% | 15.7% | -21.0% | 7.1% | -12.3% | -10.9% | -3.0% |
| ROA | -25.7% | -16.3% | -6.9% | -29.0% | 13.7% | -19.1% | 6.3% | -4.7% | -9.4% | -2.0% |
Quarterly Financials
Last 8 quarters| Metric | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $865,000 | $889,000 | $892,000 | $865,000 | $602,000 | $517,000 | $504,000 | $0 |
| Net Income | $-135,996,000 | $-106,441,000 | $-208,549,000 | $-135,996,000 | $-85,942,000 | $-126,408,000 | $-116,591,000 | $-112,152,000 |
| Total Assets | $2.3B | $2.2B | $2.0B | $2.2B | $2.3B | $2.3B | $2.4B | $2.1B |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026
Insider Trading
Loading chart...
Loading transactions...
Source: SEC EDGAR Form 4 filings. Only purchase (P) and sale (S) transactions shown.
CRISPR Therapeutics AG Free Cash Flow & Dividend Coverage
Free Cash Flow
-$345.9M
FY2025
FCF Margin
-9855.5%
FCF / Revenue
Operating Cash Flow
-$345.0M
Cash from operations
FCF / Net Income
0.59x
Below earnings
Cash Flow History
FY2016 - FY2025| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | -$4.8M | $59.4M | -$52.9M | $56.7M | -$238.4M | $539.0M | -$495.7M | -$260.4M | -$142.8M | -$345.0M |
| CapEx | -$1.2M | -$1.2M | -$3.0M | -$6.7M | -$18.4M | -$81.7M | -$37.2M | -$9.5M | -$1.9M | -$914,000 |
| Free Cash Flow | -$5.9M | $58.3M | -$55.9M | $50.0M | -$256.7M | $457.3M | -$532.9M | -$269.8M | -$144.7M | -$345.9M |
| FCF Margin | -2407.7% | 23592.7% | -1082.0% | 15241.8% | -35705.7% | 50.0% | -44484.9% | -72.7% | -387.7% | -9855.5% |
Source: SEC EDGAR 10-K filings. FCF = Operating Cash Flow - Capital Expenditures. Free cash flow guide
As of FY2025 · SEC 10-K · Updated Jul 2, 2026
CRISPR Therapeutics AG Risk Factors
Company-disclosed SEC risk factors
Risk factors are disclosed by the company in its SEC Form 10-K, Item 1A. Billiver does not classify or summarize company-specific legal, operational, financial, or market risks here.
Sector context: Health Care. This is not a Billiver risk assessment for CRSP.
Source note: the SEC Form 10-K includes Item 1A, "Risk Factors." The full risk-factor text should be read from the company’s own SEC filing.
CRISPR Therapeutics AG FAQ
What is CRISPR Therapeutics AG's annual revenue?
CRISPR Therapeutics AG (CRSP) reported $37 million in trailing twelve-month (TTM) revenue. This financial data is compiled from SEC EDGAR 10-K filings.
Does CRISPR Therapeutics AG pay dividends?
No, CRISPR Therapeutics AG (CRSP) does not currently pay dividends to shareholders.
What is CRISPR Therapeutics AG's financial health score?
CRISPR Therapeutics AG has a financial health score of 25/100 (Grade: F), evaluating profitability, solvency, liquidity, and growth based on SEC EDGAR data.
How many years of CRISPR Therapeutics AG financial data are available?
10 years of financial data are available for CRISPR Therapeutics AG from FY2016 to FY2025. All figures are compiled from SEC EDGAR 10-K filings.